| 词条 | Onepharm |
| 释义 |
| name = onepharm R & D GmbH | logo = Onepharm_logo.png | caption = | type = Private (Gesellschaft mit beschränkter Haftung) | genre = | fate = | predecessor = | successor = | foundation = {{Start date|2005|09}} | founder = Bernhard Küenburg | defunct = | location_city = Vienna | location_country = Austria | location = | locations = | area_served = | key_people = Bernhard Küenburg (CEO), Otto Dobblhoff-Dier (COO), Angelika Bodenteich (CSO) | industry = Biopharmaceutical, Drug delivery | products = Pharmaceutical drug | services = | revenue = | operating_income = | net_income = | aum = | assets = | equity = | owner = AVIR Green Hills Biotechnology, management, private investors | num_employees = 7 (2009) | parent = | divisions = | subsid = Savira Pharmaceuticals GmbH | homepage = www.onepharm.com | footnotes = }} Onepharm is a small, venture-financed Austrian biopharmaceutical company onepharm researches and develops products for periodontology. Originally focused on the development of antiviral drugs, it spun these activities out to a subsidiary, Savira Pharmaceuticals, in 2009. CreationThe creation of onepharm was triggered by the desire of its parent company, AVIR Green Hills Biotechnology to divest itself of its drug development business and to focus entirely on vaccine development.[1] The new company, which had been a finalist for the Best of Biotech award, was founded in July 2005 and became operational in September 2005, with initial funding from two Austria Wirtschaftsservice credit programs. Two of the founders took the top management positions: Bernhard Küenburg, a former Senior Vice President of Marketing, Sales and Development at Siegfried (a Swiss custom manufacturer of active pharmaceutical ingredients) became the central executive officer; and Otto Dobblhoff-Dier, a professor of bioprocess engineering who had been Vice President for global manufacturing at the Vienna cancer vaccine company Igeneon AG prior to its acquisition by Aphton Corp., became chief operating officer. Early in 2006 onepharm secured an EUR 2.7 million grant in funding from the Vienna Business Agency’s Center for Innovation and Technology, as part of a collaboration with the University of Natural Resources and Applied Life Sciences Vienna and the Vienna University of Technology. R & D focusBy 2010 onepharm has maintained its strict focus on exploiting the pharmacological potential of glycyrrhizin (the sweet-tasting triterpene glycoside in liquorice) as a lead for drug development. Elivir, a project aiming at the development of an antiviral nasal spray to treat the common cold, was in preclinical development in 2006 and was supposed to be outlicensed in 2008 after successful conclusion of Phase II clinical trials.[2] No progress has been reported, and Elivir is believed to have been discontinued. The initial intent was to develop an antiviral drug for the treatment of influenza, and possibly other viral infections such as SARS, by building and testing libraries of gylcyrrhizin derivatives at the Antiviral Spot Of Excellence" (ASPEX; a cooperation of onepharm and the Vienna universities for technology and applied life sciences). In November 2007, onepharm finalised an exclusive strategic cooperation agreement with the Japanese pharmaceutical company Minophagen, a major supplier of pharmaceutical-grade glycyrrhizin and marketer of a glycyrrhizin-based drug.[3] By this time, the company had secured an additional EUR 2 million in financing, and had moved its operations to the science park at the University of Veterinary Medicine Vienna campus. By mid-2008 onepharm had secured financing amounting to a total of EUR 8 million, and had started to build a new focus on periodontitis, based on the inhibition of inflammation-induced periodontal bone loss which the lead compound OPM-3023 had shown in a rat model. A collaboration with The Forsyth Institute, one of the world's leading centers for dental research, has been established.[4] The German health authorities have approved a Phase II clinical study with OPM-3023 in periodontitis, which is supposed to commence in 2010. A microsphere-based controlled release formulation of OPM-3023 is being developed.[5] Spin-out of Savira PharmaceuticalsIn October 2009, onepharm decided to focus entirely on the development of OPM-3023 for periodontitis. Its antiviral drug development activities were spun out to a newly created subsidiary, Savira Pharmaceuticals GmbH which was founded in cooperation with the European Molecular Biology Laboratory, with EUR 1 million funding from the Austria Wirtschaftsservice. Savira's CEO is Oliver Szolar, formerly onepharm's chief science officer. Scientific papers by onepharm
References1. ^Eurofound article on the creation of onepharm Oct. 29, 2009 [https://www.webcitation.org/5pIT1kUFm Archived] 2. ^Glycyrrhizin? Interdisziplinäre Entwicklungsarbeit! Chemiereport May 11, 2006 [https://www.webcitation.org/5pJ1euIjL Archived] 3. ^Viennese biotech start-up signs Japanese cooperation agreement Science Business Bulletin November 7, 2007 [https://www.webcitation.org/5pITsjPQs Archived] 4. ^onepharm: Passion for Innovation lisa VR news 1/2008 [https://www.webcitation.org/5pJ3s3CTo Archived] 5. ^onepharm press release June 25, 2009 and onepharm entry in Austrian Life Science Directory [https://www.webcitation.org/5pITOOOEK Archived] External links
3 : Companies based in Vienna|Pharmaceutical companies of Austria|Austrian brands |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。